High Prevalence of Chronic Diseases and Approval and Launch of New Products to Augment Growth of Array Market
The high prevalence of chronic diseases is expected to propel growth of the array market. For instance, according to the study, “Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition”, published in the journal Diabetes Research and Clinical Practice, in September 2019, 463 million people are expected to suffer from diabetes in 2019 worldwide and the number is expected to reach 578 million by 2030 and 700 million by 2045. Moreover, approval and launch of new products is also expected to aid in growth of the market. For instance, in March 2020, Agilent Technologies Inc. launched Agilent GenetiSure Cyto microarrays for prenatal and postnatal research. Similarly, the company launched three new microarrays to meet the needs of cytogenetic laboratories conducting both prenatal and postnatal research. Accuracy of arrays in determining the presence of pathogens in cannab...